Related Experiment Videos
[Paroxetine: pharmacokinetics and pharmacodynamics]
1Psychiatrische Klinik, Universität Mainz.
Fortschritte Der Neurologie-Psychiatrie
|September 1, 1994
Summary
Paroxetine, a selective serotonin reuptake inhibitor (SSRI), offers potent antidepressant effects with fewer toxic side effects than older antidepressants. Its high selectivity and low toxicity make it a potentially advantageous option, especially for elderly patients.
Area of Science:
- Pharmacology
- Neuroscience
Context:
- Paroxetine is a phenylpiperidine derivative with selective serotonin reuptake inhibition properties.
- It exhibits higher potency compared to other SSRIs.
Purpose:
- To detail the pharmacokinetic and pharmacodynamic properties of paroxetine.
- To compare its efficacy and safety profile with other antidepressant agents.
Summary:
- Paroxetine is orally administered (20-50 mg daily), with bioavailability reduced by first-pass metabolism (30-60%).
- It is metabolized in the liver into inactive compounds and highly interacts with CYP2D6, necessitating caution with co-administered drugs.
- Common side effects include nausea and somnolence, but cardiotoxicity is less frequent than with tricyclic antidepressants.
Impact:
- Paroxetine's high selectivity and low toxicity present an advantage over other antidepressants, particularly for elderly patients.
- Potential drug interactions via CYP2D6 metabolism warrant careful consideration, though significant clinical interactions are not widely reported.